Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from AstraZeneca
Information pertaining to the applications of poly(ADP-ribose) polymerase (PARP) inhibitor therapy continues to emerge at a rapid pace, with multiple PARP inhibitors approved for the treatment of patients with germline BRCA-mutated, HER2-negative breast cancer. A solid understanding of the mechanistic rationale for the use of these medications can help to optimize their potential application in the treatment of your patients. Awareness of approaches that are being studied to help maximize the efficacy of these medications, while mitigating potential treatment-related adverse events, can also help to optimize patient outcomes. It can be challenging to maintain awareness of the high volume of studies that are evaluating PARP inhibitors in different lines of therapy, both as monotherapy and in combination with other treatment modalities.
To help you meet these goals, we have developed an engaging, interactive educational activity featuring the perspectives of leading experts in the management of patients with breast cancer. Our panel will address multiple topics pertaining to the use of PARP inhibitors through a case-based format that will allow for multiple opportunities of audience interaction.
This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.
Upon completion of this activity, participants should be able to:
This activity is supported by educational grant from AstraZeneca.
Mark E. Robson, MD
Chief, Breast Medicine Service
Breast Medicine Service and Clinical Genetic Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
March 7, 2019 - March 10, 2019
March 8, 2019
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia
Mar 30, 2019
Mar 30, 2019
Mar 30, 2019